Editing Drug-induced Hypomagnesemia (TRPM7)

{{tp|p=38222324|t=2024. Multiple electrolyte disorders triggered by proton pump inhibitor-induced hypomagnesemia: Case reports with a mini-review of the literature.|pdf=|usr=}}{{38222324}}
{{tp|p=36110961|t=2022. Mass spectrometric analysis of TRPM6 and TRPM7 from small intestine of omeprazole-induced hypomagnesemic rats.|pdf=|usr=}}{{36110961}}
{{tp|p=34714373|t=2022. Proton pump inhibitors and osteoporosis risk: exploring the role of TRPM7 channel.|pdf=|usr=}}{{34714373}}
{{tp|p=23051182|t=2012. Modeling and simulation of the effect of proton pump inhibitors on magnesium homeostasis. 1. Oral absorption of magnesium.|pdf=|usr=}}{{23051182}}
{{tp|p=25138239|t=2015. Hypomagnesaemia associated with long-term use of proton pump inhibitors.|pdf=|usr=}}{{25138239}}
{{tp|p=23538697|t=2013. Proton pump inhibitors and hypomagnesemia: a rare but serious complication.|pdf=|usr=}}{{23538697}}
{{tp|p=35836357|t=2022. Severe Electrolyte Disturbances Due to Proton Pump Inhibitor Therapy: An Underrecognized Problem with Potentially Severe Sequelae.|pdf=|usr=}}{{35836357}}
{{tp|p=35652564|t=2022. Mechanisms of proton pump inhibitor-induced hypomagnesemia.|pdf=|usr=}}{{35652564}}
{{tp|p=24414180|t=2014. Lansoprazole-induced hypomagnesaemia.|pdf=|usr=}}{{24414180}}
{{tp|p=23664547|t=2013. Out-of-hospital use of proton pump inhibitors and hypomagnesemia at hospital admission: a nested case-control study.|pdf=|usr=}}{{23664547}}
{{ttp|p=36983271|t=2023. Proton Pump Inhibitors and Risk of Chronic Kidney Disease: Evidence from Observational Studies.|pdf=|usr=}}{{36983271}}
{{tp|p=33442177|t=2020. The Perilous PPI: Proton Pump Inhibitor as a Cause of Clinically Significant Hypomagnesaemia.|pdf=|usr=}}{{33442177}}
{{tp|p=31817776|t=2019. Proton-Pump Inhibitors and Hypomagnesaemia in Kidney Transplant Recipients.|pdf=|usr=}}{{31817776}}
{{tp|p=31035385|t=2019. Magnesium and Drugs.|pdf=|usr=}}{{31035385}}
{{tp|p=28078056|t=2016. Proton pump inhibitor-induced hypomagnesaemia and hypocalcaemia: case review.|pdf=|usr=}}{{28078056}}
{{tp|p=26885127|t=2015. Proton pump inhibitors use in hemodialysis patients and serum magnesium levels.|pdf=|usr=}}{{26885127}}
{{tp|p=26130997|t=2015. 'Lemonade Legs': Why do Some Patients Get Profound Hypomagnesaemia on Proton-Pump Inhibitors?|pdf=|usr=}}{{26130997}}
{{tp|p=25138239|t=2015. Hypomagnesaemia associated with long-term use of proton pump inhibitors.|pdf=|usr=}}{{25138239}}
{{tp|p=31689852|t=2019. Proton pump inhibitors and hypomagnesemia: A meta-analysis of observational studies.|pdf=|usr=}}{{31689852}}
{{tp|p=30921222|t=2019. Does the use of proton pump inhibitors increase the risk of hypomagnesemia: An updated systematic review and meta-analysis.|pdf=|usr=}}{{30921222}}
{{tp|p=34278747|t=2021. An overview of diagnosis and management of drug-induced hypomagnesemia.|pdf=|usr=}}{{34278747}}
{{tp|p=32130255|t=2020. Omeprazole use and risk of chronic kidney disease evolution.|pdf=|usr=}}{{32130255}}
{{tp|p=25268962|t=2014. Proton pump inhibitors and hospitalization with hypomagnesemia: a population-based case-control study.|pdf=|usr=}}{{25268962}}
{{tp|p=37791144|t=2023. Osmotic Demyelination Syndrome in a Normonatremic Patient Under Treatment With Proton Pump Inhibitors.|pdf=|usr=}}{{37791144}}
{{tp|p=37109245|t=2023. Effect of Long-Term Proton Pump Inhibitor Use on Blood Vitamins and Minerals: A Primary Care Setting Study.|pdf=|usr=}}{{37109245}}
{{tp|p=36794273|t=2023. Proton-pump inhibitor use amongst patients with severe hypomagnesemia.|pdf=|usr=}}{{36794273}}
{{tp|p=36769401|t=2023. Calcineurin-Inhibitor-Induced Hypomagnesemia in Kidney Transplant Patients: A Monocentric Comparative Study between Sucrosomial Magnesium and Magnesium Pidolate Supplementation.|pdf=|usr=}}{{36769401}}
{{tp|p=36514145|t=2022. Monitoring of serum magnesium levels during long-term use of proton pump inhibitors in elderly japanese patients: is it really necessary or not?|pdf=|usr=}}{{36514145}}
{{tp|p=35178215|t=2022. Relationship between long-term use of proton pump inhibitor (PPI) and hypomagnesemia in patients with gastroesophageal reflux disease.|pdf=|usr=}}{{35178215}}
{{tp|p=34466238|t=2021. Seizure and delirium secondary to carboplatin and pantoprazole therapy-induced hypomagnesemia in a cancer patient.|pdf=|usr=}}{{34466238}}
{{tp|p=34093176|t=2021. Proton Pump Inhibitor and Tacrolimus Uses are Associated With Hypomagnesemia in Connective Tissue Disease: a Potential Link With Renal Dysfunction and Recurrent Infection.|pdf=|usr=}}{{34093176}}
{{tp|p=32231419|t=2020. Effect of prolonged omeprazole administration on segmental intestinal Mg(2+) absorption in male Sprague-Dawley rats.|pdf=|usr=}}{{32231419}}
{{ttp|p=30996187|t=2019. Proton-pump Inhibitor-induced Severe Hypomagnesemia and Hypocalcemia are Clinically Masked by Thiazide Diuretic.|pdf=|usr=}}{{30996187}}
{{tp|p=30153299|t=2018. Effect of proton pump inhibitors on sympathetic hyperinnervation in infarcted rats: Role of magnesium.|pdf=|usr=}}{{30153299}}
{{tp|p=29969455|t=2018. Proton pump inhibitor as an independent factor of progression of abdominal aortic calcification in patients on maintenance hemodialysis.|pdf=|usr=}}{{29969455}}
{{tp|p=29799851|t=2018. Prevalence and outcomes of proton pump inhibitor associated hypomagnesemia in chronic kidney disease.|pdf=|usr=}}{{29799851}}
{{tp|p=29731714|t=2018. Proton Pump Inhibitors and Serum Magnesium Levels in Patients With Torsades de Pointes.|pdf=|usr=}}{{29731714}}
{{tp|p=29725641|t=2018. Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients.|pdf=|usr=}}{{29725641}}
{{tp|p=30766253|t=2017. Review of the Long-Term Effects of Proton Pump Inhibitors.|pdf=|usr=}}{{30766253}}
{{tp|p=26981439|t=2016. Proton-pump inhibitor-induced hypomagnesemia: Current research and proposed mechanisms.|pdf=|usr=}}{{26981439}}
{{tp|p=26613375|t=2016. Proton pump inhibitor associated hypomagnasaemia - a cause for concern?|pdf=|usr=}}{{26613375}}
{{tp|p=25394217|t=2014. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis.|pdf=|usr=}}{{25394217}}
{{tp|p=24175253|t=2012. Proton pump inhibitor-induced hypomagnesemia: A new challenge.|pdf=|usr=}}{{24175253}}
{{tp|p=23847429|t=2013. Effects of proton pump inhibitors and electrolyte disturbances on arrhythmias.|pdf=|usr=}}{{23847429}}
{{ttp|p=21472124|t=2011. Omeprazole decreases magnesium transport across Caco-2 monolayers.|pdf=|usr=}}{{21472124}}
{{tp|p=34275986|t=2022. Convulsive Seizure Due to Hypomagnesemia Caused by Short-term Vonoprazan Intake.|pdf=|usr=}}{{34275986}}
{{tp|p=34176835|t=2022. Severe Hypomagnesemia Associated with the Long-term Use of the Potassium-competitive Acid Blocker Vonoprazan.|pdf=|usr=}}{{34176835}}
{{tp|p=35245410|t=2022. Proton-Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition in a Population-Based Study.|pdf=|usr=}}{{35245410}}
{{tp|p=31623145|t=2019. Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome.|pdf=|usr=}}{{31623145}}